Vinci Pharmaceuticals Raises $8M+ to Advance EPIPLANT

For patients with retinal disease, treatment burden can arrive on a calendar: another appointment, another injection and another round of follow-up. Changing that routine requires more than a promising delivery mechanism because the product still has to be manufactured consistently and tested in people.

Vinci Pharmaceuticals has closed more than $8M in Series A financing to move its EPIPLANT retinal drug-delivery platform toward GMP manufacturing and a planned first-in-human study. Dynagrow Capital led the round, with support from MintPharma Capital.

The New Jersey ophthalmic biotechnology company says the financing brings its total capital raised above $16.5M after an earlier $8.5M Seed round, excluding interest on convertible notes. Vinci did not disclose the exact Series A total above $8M, valuation, ownership terms, investor allocations or board changes.

EPIPLANT is designed as a bioerodible implant placed on the outside of the eye to provide sustained delivery of small-molecule drugs to retinal tissues. The Series A gives Vinci more room to manufacture, test and release its lead VCI-002 product and prepare for a Phase 1/2a study planned for 2027. The platform has not yet produced announced human safety or efficacy data.

What Vinci Pharmaceuticals Raised

The October 8, 2026 financing announcement identifies Dynagrow Capital, LLLP as lead investor and MintPharma Capital as a supporting investor. Vinci describes the transaction as a Series A closing of more than $8M and reports cumulative financing of more than $16.5M.

The distinction between the new round and the cumulative total matters. Vinci previously raised $8.5M in Seed financing, excluding interest on convertible notes. The company has not disclosed how far above $8M the Series A closed, so the defensible deal record is $8M+, not a reconstructed figure from private-company databases.

Vinci expects to use the proceeds for GMP manufacturing, testing and release activities for EPIPLANT VCI-002 and preparation for a first-in-human Phase 1/2a study in 2027. Manufacturing under controlled conditions is part of the clinical story because a study cannot interpret a product that cannot be produced and released consistently.

How EPIPLANT Is Designed to Work

EPIPLANT was developed in the laboratory of co-founder Karl Csaky, MD, PhD and licensed from the Retina Foundation. Vinci describes the platform as an episcleral implant, meaning it sits on the outer surface of the eye rather than being injected into the vitreous cavity, and is designed to deliver medication toward retinal tissue over time.

The company says the bioerodible platform can carry different small-molecule active ingredients, creating the possibility of multiple retinal-disease programs from one delivery architecture. Vinci also reports preliminary preclinical testing and multiple patents. A reviewed public patent application, US20240374372A1, is assigned to Vinci and names Csaky and co-founder Philip Gioia as inventors.

Those records establish that the technology and intellectual-property work exist. They do not establish how the implant will behave in a human eye, how long drug exposure will remain therapeutic, whether the procedure will be tolerated or whether the platform will improve outcomes or adherence. Those questions belong to clinical development.

Why the Manufacturing Handoff Matters

Retinal therapies can create a recurring burden for patients and physicians because many medicines are delivered through injections into the eye. Vinci is pursuing a different delivery location and longer-duration exposure, an approach that could become meaningful if it can provide controlled drug levels without introducing a different set of safety or procedural problems.

The company is targeting retinal conditions that include diabetic macular edema and intermediate age-related macular degeneration. Vinci presents both as large markets with unmet need, but market size is only the outer frame. A useful product still has to match a disease, a molecule, a dose, a release profile and a clinical endpoint that shows patients are better off.

That is why the work financed by this round sounds less glamorous than the headline and matters more. GMP production, release specifications, stability, study design, investigator readiness and regulatory preparation turn a laboratory mechanism into something a clinical team can evaluate. Each step narrows uncertainty before the next one becomes expensive.

The People and Capital Behind Vinci

Philip A. Gioia is Vinci's co-founder, chairman and CEO. Gioia brings commercial and business-development experience across ophthalmology and pharmaceuticals, while Csaky's work at the Retina Foundation connects the company to retinal research and ocular drug-delivery development.

Dynagrow Capital is financing the lead position in the Series A. MintPharma Capital, which lists Vinci in its official portfolio, says it typically invests in late-preclinical and early-clinical biotechnology companies. That stage focus fits the task in front of Vinci: pay for the transition into human evidence before the result is known.

The financing announcement includes no independently audited performance metrics, commercial revenue or patient outcomes. It also does not identify a registered trial, enrollment site, first-patient date or regulatory clearance to begin the planned study. The company has defined the next development objective, while the schedule remains a forward-looking plan.

What the 2027 Study Needs to Establish

Vinci plans to take VCI-002 into a Phase 1/2a study in 2027. Early clinical work will need to establish basic safety and tolerability while beginning to characterize drug delivery, exposure and any preliminary signal relevant to the chosen retinal indication. The final design, endpoints, enrollment and follow-up will matter more than the phase label alone.

The retinal field already knows how compelling a delivery story can sound before human data arrives. DevCuration's coverage of Ray Therapeutics shows a different retinal program confronting the same broad discipline: mechanism, funding and regulatory progress do not substitute for patient-level evidence.

Vinci's Series A is therefore best understood as capital for an evidence handoff. Gioia, Csaky, Dynagrow and MintPharma are moving EPIPLANT from preclinical promise toward the controlled manufacturing and clinical process that can challenge its assumptions. The next meaningful record will be built less by the financing headline than by the product specifications, investigators and patients carrying the program into its first human data.